Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Medical Marijuana, Inc. Subsidiary HempMeds® Mexico Announces Participation at 32nd International Congress of Epilepsy in Barcelona

Medical Marijuana,Inc.
Posted on: 30 Aug 17

PR Newswire

SAN DIEGO, Aug. 30, 2017

SAN DIEGO, Aug. 30, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that subsidiary HempMeds® Mexico product Real Scientific Hemp Oil-X will be featured at the 32nd International Congress of Epilepsy in Barcelona, Spain from September 2-6, 2017.

Mexican pediatric neurologist, Dr. Saul Garza will be presenting a poster at the International Congress for Epilepsy which outlines his clinical study using RSHO-X as a method of treatment for Lennox-Gastaut Syndrome (LGS). The presentation will be at 1:30 p.m. on Sunday, September 3.

The study included 39 patients with Lennox-Gastaut syndrome, a severe form of pediatric epilepsy that typically develops before the age of four. Of those 39 patients, which took up to 5-7mg CBD/kg of body weight in progressive doses of RSHO-X™ 5000MG: an 84% average reduction in motor seizures were experienced; 53% of patients reported better than a 75% reduction in seizures; and 17% reported a complete elimination of all seizures over a 4-month period. No adverse side effects were reported among the patient population.

"We are thrilled that Dr. Garza was chosen to present his findings at the International Congress of Epilepsy as this study shows our botanical CBD to provide the best available therapeutic intervention within this epilepsy patient population.  Given the advanced nature of these children's conditions, it is pretty remarkable that 17% of the Lennox-Gastaut Syndrome patients experienced a total, 100% relief from their seizure episodes," said CEO of Medical Marijuana, Inc. Dr. Stuart Titus. "Studies like Dr. Garza's help prove that the therapeutic benefits of botanically-oriented CBD are real and are helping fuel increased access to medical cannabis programs across the globe."

In Mexico, the use of cannabis products for medical purposes was especially important since when in 2015 the case of the girl, Graciela Elizalde Benavides, diagnosed with Lennox-Gastaut syndrome was suffering up to 400 seizures daily. After a legal battle accompanied by strong social pressure, the country 's government authorized the therapeutic use with a derivative of cannabis solely for this patient, the main milestone for a revolution that allowed Dr. Garza and companies like HempMeds® to provide support for the initiative promoting access to treatment derived from cannabis for thousands of Patients with a variety of indications.

Now with Mexico allowing the use, sale, export and import of medical cannabis, other countries like the United States, Brazil and Canada, are also making strides in the therapeutic use of cannabis products. In Europe legalization of these products is currently underway, with countries such as Austria, Belgium, Croatia, Italy, Poland, Macedonia and recently Germany having already legalized the usage of cannabis for medicinal purposes.

About HempMeds® Mexico

HempMeds® Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company's website at: http://www.hempmeds.mx

About Medical Marijuana, Inc:

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

FORWARD-LOOKING DISCLAIMER AND DISCLOSURES

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

The statements in this press release have not been evaluated by the Food and Drug Administration (FDA) and are not intended to diagnose, treat or cure any disease.  The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.

Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829-0070
andrew.hard@cmwmedia.com

 

View original content with multimedia:http://www.prnewswire.com/news-releases/medical-marijuana-inc-subsidiary-hempmeds-mexico-announces-participation-at-32nd-international-congress-of-epilepsy-in-barcelona-300511306.html

SOURCE Medical Marijuana, Inc.

PR Newswire
www.prnewswire.com

Last updated on: 30/08/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.